Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Comparable maintenance of efficacy was observed between tralokinumab and lebrikizumab after 52 weeks of treatment among patients meeting response criteria at week 16.
Authors
- Naiem Tony Issa (ORCID: https://orcid.org/0000-0002-5885-3909)
- Matthias Augustin (ORCID: https://orcid.org/0000-0002-4026-8728)
- Rie von Eyben (ORCID: https://orcid.org/0000-0003-2355-8667)
- A Petersen (ORCID: https://orcid.org/0000-0001-7286-5239)
- Tiago Torres (ORCID: https://orcid.org/0000-0003-0404-0870)
- April W. Armstrong (ORCID: https://orcid.org/0000-0002-6892-6286)
- Teodora Festini
Institutions
- University of Miami (US)
- Universität Hamburg (DE)
- University of California, Los Angeles (US)
- Universidade do Porto (PT)
- George Washington University (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Forefront of Dermatology (US)
- Centro Hospitalar do Porto (PT)
- Leo Pharma (Denmark) (DK)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1007/s13555-025-01563-3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- LEO Pharma